RockStep Solutions and the Novartis in vivo study teams worked together for over year to design and develop software that is transforming how discovery workflows are conducted. The goal of the effort was to build the best in vivo software possible using “future proof” technologies and engineering practices. The project was lead by RockStep’s co-founder and President, Julie Morrison and members of the Novartis Head of Emerging Technologies working closely with the in vivo study team scientists, managers, and technicians. Julie Morrison, is also one of the Pistoia Alliance UXLS champions. The full article was published in Drug Discovery World.